Acalabrutinib, ibrutinib, and zanubrutinib are representatives of BTK inhibitors that are approved in the treatment of certain lymphomas.278 The attempt for use of BTK inhibitors in COVID-19 treatment is limited in small-scale retrospective clinical studies. Here, BTK is linked to lymphoma.